Skip to main content
TipRanks
Go Ultimate75% OFF

MedinCell SA (MDCLF) Q4 2026 Earnings Report

0 Followers

MDCLF Q4 2026 EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.16
Beat/Miss
Missed by -$0.35
One Year Ago EPS
-$0.13

MDCLF Q4 2026 Revenue Results

Actual Revenue
$8.82M
Expected Revenue
$17.95M
Beat/Miss
Missed by -$9.13M
YoY Revenue Growth
-52.91%

Earnings Announcement Details

Quarter
Q4 2026
Date
06/16/2026
Time
During Market Hours
Conference Call
Tuesday, June 16, 2026
MDCLF Upcoming Earnings

MedinCell SA's next earnings date is estimated for December 9, 2026, based on past reporting schedules.

Q4 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q4 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q4 2026 Earnings Call Summary

Q4 2026
Earnings Call Date:Jun 16, 2026|% Change Since:-12.01%|
Earnings Call Sentiment|Positive

The call presents a largely positive strategic picture: strong commercial traction for UZEDY with high-teens to double-digit growth rates, clear regulatory progress for olanzapine LAI (NDA accepted) and an expanding partnered pipeline (15 formulation-stage programs, AbbVie program advancing toward clinic). Management is intentionally increasing investment to accelerate R&D and business development, which drove higher operating expenses and resulted in an operating and net loss this fiscal year, and there are near-term accounting and FX headwinds (non-cash EIB warrant revaluation, USD exposure) as well as some program-specific regulatory uncertainty. Overall, the company is in a transitional, investment-heavy phase with improving recurring royalty revenue that supports a positive outlook if commercial ramps and regulatory approvals proceed as expected.

Company Guidance

Management provided detailed forward guidance focused on three growth engines: UZEDY, olanzapine LAI and a broader pipeline. Key metrics: Teva reported UZEDY net sales of $250m in FY2025/26 (vs $141m prior year) driving royalties to $10.9m (+54% YoY in USD; +42% in EUR to €9.3m), Q1‑2026 sales of $63m (+62% YoY), and Teva’s initial 2026 guidance of $250–$280m (management now sees ~ $300m potential for 2026 and expects blockbuster trajectory into the early 2030s). Olanzapine LAI: NDA accepted Feb‑2026 and EU MAA submitted, targeting U.S. launch in Q4‑2026 (first royalties potentially as early as Q4‑2026) with “meaningful” revenues expected from H2‑2027 and a faster ramp than UZEDY. Pipeline/platform metrics: >4,000 subQ injections with no PDSS, 15 programs in formulation (7 internal, 8 partner‑funded), CMC for the AbbVie program completing this year with a clinical start in 2027, and mdc‑CWM Phase‑III prep/initiation expected in 2026. Financial context/guidance drivers: total income €24.3m (vs €27.7m), royalties = 38% of revenue (vs 22% prior year), OpEx €45m (vs €38.5m) with R&D ≈60% of OpEx, operating loss €20.8m, net loss €31.3m, cash €80.8m (net cash €15.3m), €6.4m AbbVie collaboration revenue, €1.6m early‑stage partner revenues, and no milestone this year (prior year included a €4.8m olanzapine milestone).

  • Strong UZEDY Commercial MomentumTeva-reported net sales for UZEDY reached $250 million in FY 2025/2026 versus $141 million prior year (≈+77%), driving royalty growth to $10.9 million from $7.1 million in USD (≈+54%). Q1 2026 net sales were $63 million, up 62% year-over-year, and Teva provided an initial 2026 guidance range of $250M–$280M with expectations close to $300M for the year.
  • Increasing Royalty-driven Revenue MixRoyalty income increased to 38% of total revenue this year versus 22% last year (a +16 percentage point shift), illustrating a structural move toward recurring royalty revenues. Revenues excluding milestone variability rose from EUR 22.9 million to EUR 24.3 million (+~6.1%) and have been multiplied by three over the last two years when excluding milestones.
  • Olanzapine LAI Regulatory Progress and DifferentiationOlanzapine LAI NDA was submitted Dec 2025 and accepted by the FDA in Feb 2026; MAA submitted in Europe. Company expects a U.S. launch in Q4 2026 subject to approval, with first royalties potentially beginning in Q4 2026. Medincell's subcutaneous formulation has >4,000 clinical injections with no PDSS events observed, supporting a differentiated safety profile versus existing intramuscular formulations.
  • Pipeline Expansion and Partnership ExecutionMedincell has 15 active programs at formulation stage (7 internal, 8 partner-funded). The AbbVie collaboration advanced toward clinic with CMC expected to complete in 2026 supporting a clinical start by the partner in 2027. mdc-CWM (post-TKR pain) phase III preparation is ongoing with initiation expected in 2026.
  • Strategic R&D Investment to Support GrowthOperating expenses intentionally increased to EUR 45.0 million from EUR 38.5 million (+~16.9%) to scale R&D and BD efforts. R&D represents ~60% of OpEx, reflecting investment in the BEPO platform, BEPO Star and next-generation formulations to expand into higher-dose and more hydrophilic molecules (e.g., GLP‑1s).
  • Improved Balance Sheet and LiquidityCash and financial deposits at period end were EUR 80.8 million, and cash position net of debt was positive at EUR 15.3 million, providing runway and financial flexibility to support the multi-engine growth strategy.
  • Commercial and Label Milestone for UZEDYUZEDY received an FDA label expansion into bipolar I disorder for the one‑month formulation in October 2025, broadening the commercial opportunity and supporting further prescription growth.

MDCLF Earnings History

MDCLF earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Dec 09, 20262027 (Q2)-0.12--0.55――
Jun 16, 20262026 (Q4)-0.16-0.50-0.13-275.00% (-0.37)
Dec 09, 20252026 (Q2)-0.20-0.55-0.562.00% (+0.01)
Jun 17, 20252025 (Q4)-0.19-0.13-0.6880.33% (+0.55)
Dec 10, 20242025 (Q2)-0.21-0.56-0.33-70.65% (-0.23)
Jun 10, 20242024 (Q4)―-0.68-0.8115.75% (+0.13)
Dec 19, 20232024 (Q2)―-0.33-0.6146.73% (+0.29)
Jun 26, 20232023 (Q4)―-0.81-0.58-38.43% (-0.22)
Dec 06, 20222023 (Q2)―-0.61-0.52-17.02% (-0.09)
Jun 14, 20222022 (Q4)―-0.58-0.37-56.12% (-0.21)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed